Results 151 to 160 of about 46,447 (205)

Patient-Derived Organoid and Single-Cell Multiomics Reveal Evolution Driven by CEACAM6/KRT19-Mediated Heterogeneity. [PDF]

FASEB J
Jing C, Wang Z, Cao H, Zhang Y, Huang Y, Yu Y, Li B, Ma R.   +7 more
europepmc   +1 more source

Extending the utility of anti-EGFR therapy in metastatic colorectal cancer. [PDF]

J Gastrointest Oncol
Cann C, Vijayvergia N.
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Impact of <i>UGT1A1*28</i> polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial. [PDF]

Future Oncol
Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A.   +10 more
europepmc   +1 more source

Recurrent Mandibular Ewing sarcoma in an 11-year-old boy: a rare pediatric case and review of the literature. [PDF]

J Med Case Rep
Nourbakhsh SMK, Shirkhoda M, Jangjoo T.
europepmc   +1 more source

Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report. [PDF]

Surg Case Rep
Akahori T, Yokotani T, Yoshizawa A, Uchiyama T, Yamaguchi R, Sho M.   +5 more
europepmc   +1 more source

The Dual Role of Human UDP-Glucuronosyltransferase-Mediated Metabolism in Tumor Drug Resistance: Mechanisms and Prospects. [PDF]

Int J Mol Sci
Wang Z, Zhong J, Ren C, Shi H, Fang X, Xiao X, Liu X, Cao D, Zeng X.   +8 more
europepmc   +1 more source

Single-center Experience with Comprehensive Genomic Profiling Using Circulating Tumor DNA for Metastatic Colorectal Cancer. [PDF]

J Anus Rectum Colon
Ito K, Kataoka K, Muroi Y, Koba M, Fukumoto Y, Imada A, Jihyung S, Rao Z, Osumi H, Uchino M, Kimura K, Ikeda M.   +11 more
europepmc   +1 more source

Irinotecan plus temozolomide for pediatric relapsed or refractory solid tumors: a retrospective cohort study. [PDF]

Transl Pediatr
Fang J, Zhang Y, Liu Q, Dong Z, Gong H, Zhou W, Wang Y, Liu H.   +7 more
europepmc   +1 more source